Clinical Trials on Intercritical Gout in Argentina

Total 5 results

Novartis Pharmaceuticals

Terminated

Safety & Efficacy of Canakinumab (ACZ885) in Patients With Frequent Flares for Whom Nonsterodial Anti-Inflammatory Drug (NSAIDs) and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective

Gouty Arthritis

China, Poland, Singapore, Argentina
Novartis Pharmaceuticals

Completed

Long Term Study of Canakinumab (ACZ885) in Patients With Gout

Gouty Arthritis

Colombia, Spain, Taiwan, Russian Federation, Guatemala, Belgium, United States, Argentina, Czechia, Germany, Hungary, Poland, Portugal, Singapore, Slovakia, South Africa, Turkey, United Kingdom
Future Biome SA

Recruiting

Fungal Fiber for Gut Health (FUN4GUT)

Immune Response | Stress | Nutrition, Healthy | Gut Microbiome | Low-grade Chronic Inflammation | Activity of Daily Living | Gut Health | Mild Gastrointestinal Symptoms in Healthy Adults | Gut Permeability

Argentina
Novartis

Completed

Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients

Acute Gout

United States, Russian Federation, Switzerland, Germany, Turkey, Poland, Argentina, Canada, Belgium, France, United Kingdom
Novartis Pharmaceuticals

Completed

A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)

Gout

United States, Colombia, Russian Federation, Taiwan, Argentina, Turkey, Germany, Singapore, Spain, Hungary, Guatemala, Poland, South Africa, Slovakia, Portugal, Belgium, Czechia, United Kingdom

Clinical Trials on Intercritical Gout in Argentina

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations